Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APTO NASDAQ:DBVT NASDAQ:MESO NASDAQ:SRRK NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsDBVTDBV Technologies$16.31-3.8%$11.04$2.20▼$18.00$464.35M-0.45162,393 shs55,896 shsMESOMesoblast$17.65+3.4%$16.08$7.09▼$22.00$2.18B2.3259,147 shs199,070 shsSRRKScholar Rock$27.92-0.1%$33.67$22.71▼$46.98$2.69B0.423.85 million shs3.92 million shsVCELVericel$36.02+2.0%$33.71$29.24▼$63.00$1.78B1.39684,448 shs411,112 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%0.00%-84.35%DBVTDBV Technologies-3.78%-0.67%+71.68%+75.75%+362.63%MESOMesoblast+3.40%-2.70%+3.76%+17.04%+77.21%SRRKScholar Rock-0.07%-18.55%-9.47%-30.17%-8.61%VCELVericel+1.98%+7.55%+13.70%-5.16%-13.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsDBVTDBV Technologies$16.31-3.8%$11.04$2.20▼$18.00$464.35M-0.45162,393 shs55,896 shsMESOMesoblast$17.65+3.4%$16.08$7.09▼$22.00$2.18B2.3259,147 shs199,070 shsSRRKScholar Rock$27.92-0.1%$33.67$22.71▼$46.98$2.69B0.423.85 million shs3.92 million shsVCELVericel$36.02+2.0%$33.71$29.24▼$63.00$1.78B1.39684,448 shs411,112 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%0.00%-84.35%DBVTDBV Technologies-3.78%-0.67%+71.68%+75.75%+362.63%MESOMesoblast+3.40%-2.70%+3.76%+17.04%+77.21%SRRKScholar Rock-0.07%-18.55%-9.47%-30.17%-8.61%VCELVericel+1.98%+7.55%+13.70%-5.16%-13.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences 3.50Strong Buy$6.00∞ UpsideDBVTDBV Technologies 2.43Hold$14.75-9.56% DownsideMESOMesoblast 2.80Moderate Buy$24.0035.98% UpsideSRRKScholar Rock 3.07Buy$48.5073.71% UpsideVCELVericel 2.71Moderate Buy$58.4062.13% UpsideCurrent Analyst Ratings BreakdownLatest SRRK, VCEL, MESO, DBVT, and APTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025SRRKScholar RockTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$54.00 ➝ $44.0010/15/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$46.00 ➝ $41.0010/14/2025VCELVericelZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/9/2025SRRKScholar RockBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$53.0010/8/2025DBVTDBV TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MESOMesoblastWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SRRKScholar RockWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VCELVericelWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/29/2025DBVTDBV TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/27/2025DBVTDBV TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MESOMesoblastWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/ADBVTDBV Technologies$4.15M107.69N/AN/A$1.42 per share11.49MESOMesoblast$17.20M131.35N/AN/A$4.67 per share3.78SRRKScholar Rock$33.19M80.87N/AN/A$3.94 per share7.09VCELVericel$237.22M7.66$0.32 per share113.03$5.92 per share6.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/ADBVTDBV Technologies-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%11/5/2025 (Estimated)MESOMesoblast-$102.14MN/A0.00N/AN/AN/AN/AN/AN/ASRRKScholar Rock-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)VCELVericel$10.36M$0.12300.1981.86N/A2.85%2.47%1.69%11/6/2025 (Estimated)Latest SRRK, VCEL, MESO, DBVT, and APTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025SRRKScholar Rock-$0.88N/AN/AN/A$0.05 millionN/A11/6/2025Q3 2025VCELVericel-$0.02N/AN/AN/A$64.57 millionN/A11/5/2025Q3 2025DBVTDBV Technologies-$1.45N/AN/AN/A$0.76 millionN/A8/6/2025Q2 2025SRRKScholar Rock-$0.66-$0.98-$0.32-$0.98$0.11 millionN/A7/31/2025Q2 2025VCELVericel-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 million7/29/2025Q2 2025DBVTDBV Technologies-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A1.051.05DBVTDBV TechnologiesN/A2.452.45MESOMesoblast0.111.991.77SRRKScholar Rock0.216.336.33VCELVericelN/A4.974.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%DBVTDBV Technologies71.74%MESOMesoblast1.43%SRRKScholar Rock91.08%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences1.33%DBVTDBV Technologies1.44%MESOMesoblast18.80%SRRKScholar Rock13.30%VCELVericel7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences312.14 million63.45 millionNo DataDBVTDBV Technologies8027.40 million27.00 millionOptionableMESOMesoblast80128.00 million103.93 millionOptionableSRRKScholar Rock14096.13 million83.34 millionOptionableVCELVericel30050.46 million46.83 millionOptionableSRRK, VCEL, MESO, DBVT, and APTO HeadlinesRecent News About These CompaniesTruist Lowers PT on Vericel Corporation (VCEL) to $41 From $46October 20 at 11:30 PM | insidermonkey.comConestoga Capital Advisors LLC Buys 401,990 Shares of Vericel Corporation $VCELOctober 20 at 3:33 AM | marketbeat.comWilliam Blair Investment Management LLC Sells 123,021 Shares of Vericel Corporation $VCELOctober 19 at 5:20 AM | marketbeat.comVericel (NASDAQ:VCEL) Trading Up 5.6% - Here's What HappenedOctober 17, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Upgraded by Zacks Research to "Strong-Buy" RatingOctober 16, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Acquires 610,045 Shares of Vericel Corporation $VCELOctober 16, 2025 | marketbeat.comAberdeen Group plc Buys Shares of 209,217 Vericel Corporation $VCELOctober 16, 2025 | marketbeat.comVericel price target lowered to $41 from $46 at TruistOctober 16, 2025 | msn.comTruist Securities Maintains Vericel (VCEL) Buy RecommendationOctober 16, 2025 | msn.comLeerink Partnrs Has Pessimistic View of Vericel Q4 EarningsOctober 15, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 15, 2025 | americanbankingnews.comVericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 10, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Receives "Sell (D+)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comVericel Corporation $VCEL Shares Purchased by PFG Investments LLCOctober 4, 2025 | marketbeat.comCanaccord Genuity Keeps Their Buy Rating on Vericel (VCEL)September 26, 2025 | theglobeandmail.comVericel Corporation $VCEL Shares Acquired by Congress Asset Management Co.September 26, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Hits New 12-Month Low - Time to Sell?September 25, 2025 | marketbeat.comKopp Family Office LLC Sells 8,554 Shares of Vericel Corporation $VCELSeptember 24, 2025 | marketbeat.comVoya Investment Management LLC Purchases 10,048 Shares of Vericel Corporation $VCELSeptember 24, 2025 | marketbeat.comDeclining Stock and Decent Financials: Is The Market Wrong About Vericel Corporation (NASDAQ:VCEL)?September 18, 2025 | finance.yahoo.comVericel downgraded to Neutral from Buy at BTIGSeptember 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRRK, VCEL, MESO, DBVT, and APTO Company DescriptionsAptose Biosciences NASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.DBV Technologies NASDAQ:DBVT$16.31 -0.64 (-3.78%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$16.26 -0.05 (-0.34%) As of 10/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Mesoblast NASDAQ:MESO$17.65 +0.58 (+3.40%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$17.84 +0.19 (+1.08%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Scholar Rock NASDAQ:SRRK$27.92 -0.02 (-0.07%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$28.63 +0.71 (+2.54%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Vericel NASDAQ:VCEL$36.02 +0.70 (+1.98%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$36.80 +0.78 (+2.18%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
